TORONTO, CANADA–(Marketwire – March 15, 2012) – Arch Biopartners Inc. (“Arch” or the “Company”) (CNSX:ACH)(OTCBB:FOIFF) today announced that the National Research Council of Canada – Industrial Research Assistance Program (NRC-IRAP) has approved funding up to $107,000 to assist Arch in the development of diagnostic imaging applications for its brain tumour initiating cell (“BTIC”) targeting technology.
Press Releases
Arch Scientists to Lead Anti Corrosion Project for Auto Industry
TORONTO, ONTARIO–(Marketwire – Feb. 28, 2012) – Arch Biopartners Inc. (“Arch” or the “Company”) (CNSX:ACH)(OTCBB:FOIFF) today announced that AUTO21 and its contributing partners have approved funding totaling $518,400 for Arch scientists to lead an anti corrosion project on Magnesium (“Mg”) and rare earth (“RE”) alloys for the Canadian auto industry.
Arch Biopartners Appoints Claude Allary as Special Advisor
TORONTO, ONTARIO–(Marketwire – Jan. 24, 2012) – Arch Biopartners Inc (“Arch” or the “Company”) (CNSX:ACH)(OTC:FOIFF) announced today Claude Allary has been appointed Special Advisor to the Company. In this capacity, Mr. Allary will provide expertise in evaluating commercial opportunities for the Company’s drug development platforms and other emerging technologies.
Arch Scientists Inhibit Biofilm Formation and Increase Hardness on Titantium
TORONTO, ONTARIO–(Marketwire – Dec. 19, 2011) – Arch Biopartners Inc (“Arch” or the “Company”) (CNSX:ACH)(OTC:FOIFF) and its subsidiary Arch Biophysics Ltd today announced that Arch scientists have inhibited biofilm formation on titanium using the Company’s proprietary peptide technology.
Arch Biopartners Engages Intertek Cantox to Devise Drug Development Plan for Lead Cancer Compound
TORONTO, ONTARIO–(Marketwire – Nov. 7, 2011) – Arch Biopartners Inc (“Arch” or the “Company”)(CNSX:ACH)(OTC:FOIFF) today announced it has engaged Intertek Cantox (“Cantox”) to devise the drug development plan for the Company’s lead compound, GH501a.
Arch Biopartners Identify Lead Compound for Pancreatic Cancer and Non Small Cell Lung Cancer
TORONTO, ONTARIO–(Marketwire – Sept. 7, 2011) – Arch Biopartners Inc (“Arch” or the “Company”) (CNSX:ACH)(OTC:FOIFF) today announced it has identified a lead compound, named GH501a, for further development as potential treatment for non small cell lung cancer and pancreatic cancer.
Arch Biopartners Hires Investor Relations Firm
TORONTO, ONTARIO–(Marketwire – July 18, 2011) – Arch Biopartners Inc (“Arch” or the “Company”)(CNSX:ACH)(OTC:FOIFF) announced today it has retained the services of Renmark Financial Communications Inc. (Renmark”) to perform investor relations activities.
Arch Biopartners Announces Issuance of New U.S. Patent for Biofilm Inhibitor
TORONTO, ONTARIO–(Marketwire – July 14, 2011) – Arch Biopartners Inc (“Arch” or the “Company”)(CNSX:ACH)(OTC:FOIFF) today announced the U.S. Patent and Trademark Office has issued a method and composition patent for an invention preventing or inhibiting the growth of biofilm formation on biotic and abiotic surfaces.
Arch Biopartners, U of Calgary Extend Agreement
TORONTO, ONTARIO–(Marketwire – July 6, 2011) – Arch Biopartners Inc (“Arch” or the “Company”)(CNSX:ACH)(OTC:FOIFF) today announced that the University of Calgary has extended the overhead agreement with its subsidiary Arch Biotech Inc.
Arch Biopartners Enters Agreement to Develop Prototype Diagnostic Imaging Agents for Brain Tumor Stem Cells
TORONTO, ONTARIO–(Marketwire – June 27, 2011) – Arch Biopartners Inc (“Arch” or the “Company”) (CNSX:ACH)(OTC:FOIFF) and its subsidiary Arch Cancer Therapeutics (“ACT”) today announced ACT has entered into an Agreement for Research Services (the “Agreement”) with the National Research Council of Canada (NRC).